N-of-1 Trial¶
A prospective within-person experiment in which one participant receives comparative intervention conditions over multiple planned periods to estimate that individual's treatment response.
Core Idea¶
An N-of-1 trial brings controlled comparison inside one participant. Two or more treatment conditions are administered across multiple periods, commonly as repeated crossover pairs or blocks. Randomizing order, masking treatment identity, standardizing outcomes, and replicating periods reduce alternative explanations, although not every design can use every safeguard.
Scope of Application¶
- Chronic stable conditions. Repeatedly measurable symptoms can be compared across reversible treatment periods.
- Individual treatment selection. The participant's comparative benefit and harms can inform a shared clinical decision.
- Rare or heterogeneous conditions. Within-person evidence can complement sparse group evidence when crossover assumptions hold.
- Series of N-of-1 trials. Several individual experiments can be prospectively aggregated without erasing participant-specific effects.
Clarity¶
A report should state the participant, treatments, period length, randomization, masking, run-in, washout, outcome timing, carryover model, analysis, stopping rule, adverse events, and missing data. AB or ABA notation alone does not establish a rigorous trial. The design estimates what happened under specified periods; irreversible interventions, progressive disease, and long delayed effects may make crossover invalid.
Manages Complexity¶
Repeated crossover uses the participant as their own control, reducing stable between-person variation and directly targeting personal response. Time remains a confounder: trends, period effects, anticipation, adherence, and residual treatment can mimic a difference. Replication, randomization, washout, and time-series analysis manage those sources only when their assumptions are credible.
Abstract Reasoning¶
- Define the individualized decision and treatments worth comparing.
- Check reversibility, onset, washout, outcome sensitivity, and condition stability.
- Prespecify periods, randomization, masking, measures, analysis, stopping, and safety rules.
- Collect outcomes and adherence consistently through every period.
- Estimate the within-person contrast with period, trend, and carryover effects represented.
Knowledge Transfer¶
The design transfers across clinical questions when repeated assigned exposure is ethical, effects are reversible, and outcomes are timely. Personal productivity experiments may share the crossover structure but are not clinical trials without the health intervention, ethics, and oversight context. Group crossover trials use related logic across several participants but have different estimands.
Relationships to Other Abstractions¶
Current abstraction N-of-1 Trial Domain-specific
Parents (1) — more general patterns this builds on
-
N-of-1 Trial is a kind of Experimental Design Prime
An N-of-1 Trial is an Experimental Design that deliberately assigns comparative treatment conditions across planned periods within one participant.
Hierarchy paths (2) — routes to 1 parentless root
- N-of-1 Trial → Experimental Design → Control Sample → Comparison → Self Checking
- N-of-1 Trial → Experimental Design → Comparison → Self Checking
Neighborhood in Abstraction Space¶
N-of-1 Trial sits in a crowded region of the domain-specific corpus (38th percentile for distinctiveness): several abstractions share nearly its structure, so a description that fits it tends to fit its neighbors too.
Family — Developmental & Clinical Mechanism Hypotheses (13 abstractions)
Nearest neighbors
- Kruskal–Wallis Test — 0.89
- Drug Accumulation Ratio — 0.88
- Behavioral Effect — 0.88
- Experiment (Probability Theory) — 0.88
- Petrie multiplier — 0.87
Computed from structural-signature embeddings · 2026-10-08